Exacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study
15 affiliations
- 1Department of Pulmonary, Allergy and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul 05355, Republic of Korea
- 2Department of Internal Medicine, Medical School of Yeungnam University, Daegu 42415, Republic of Korea
- 3Department of Pulmonology and Allergy, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea
- 4Department of Internal Medicine, Dong-A University College of Medicine, Busan 49201, Republic of Korea
- 5Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan 48108, Republic of Korea
- 6Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan 49267, Republic of Korea
- 7Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea
- 8Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong 18450, Republic of Korea
- 9Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Republic of Korea
- 10Department of Allergy, Keimyung University School of Medicine, Daegu 42601, Republic of Korea
- 11Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
- 12Division of Allergy, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
- 13Department of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Republic of Korea
- 14Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon 16499, Republic of Korea
- 15Clinical Trial Center, Ajou University Medical Center, Suwon 16499, Republic of Korea
Abstract
Concerns about worsening allergic disease may contribute to vaccine hesitancy. We evaluated the frequency, severity, and factors associated with self-reported exacerbations after COVID-19 vaccination and described findings after influenza vaccination. In this multicenter observational survey, adults with physician-diagnosed allergic diseases were prospectively enrolled at 14 Korean allergy centers, while vaccination history and post-vaccination outcomes were retrospectively ascertained. Severe exacerbation was defined as requiring emergency department care or hospitalization. Among 1626 COVID-19-vaccinated patients, 281 (17.3%) reported exacerbation; 36 (12.8% of exacerbators; and 2.2% of all vaccinated patients) were severe. Female sex, chronic urticaria, and atopic dermatitis were independently associated with any exacerbation, whereas increasing age and allergic rhinitis were associated with lower odds. Bronchial asthma was independently associated with severe exacerbation (adjusted OR, 3.07; 95% CI, 1.10–8.51). No factor was associated with multiple exacerbations. Biologic therapy and allergen immunotherapy were not associated with increased risk. Exacerbations were reported in 16 of 786 influenza-vaccinated patients (2.0%) and were generally mild. Although self-reported symptom worsening after COVID-19 vaccination was relatively common, severe events were uncommon. COVID-19 vaccination was generally well tolerated, including among patients receiving biologics or allergen immunotherapy.
Related
- m6A modification in allergic airway diseases: a narrative review from a cellular perspective
- Phenotypes of Atopic Dermatitis and Development of Allergic Diseases
- DNA methylation predicts lung function and pulmonary exacerbation in sputum samples from patients with cystic fibrosis
- Properties of the Isolated Strain of Pseudobutyrivibrio sp. and Its Effect on the Alleviation of Allergic Dermatitis in a Mouse Model
- Gut microbiota alters the Th1/Th2 balance and aggravates food-allergic enteropathy in a mouse model
BibTeX
@article{ban2026exacerbation,
title = {{Exacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study}},
author = {Ga-Young Ban and Hyun Jung Jin and Ji-Ho Lee and Young-Hee Nam and Hyo-In Rhyou and Gil-Soon Choi and Gyu Young Hur and Jeong-Hee Choi and Joo-Hee Kim and Chang-Gyu Jung and Seong-Dae Woo and Hwa Young Lee and Mi-Ae Kim and Youngsoo Lee and Sang-Ha Kim and Hyun-Young Lee and Young-Min Ye},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210277},
url = {https://www.mdpi.com/1422-0067/27/22/10277},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Exacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study
AU - Ga-Young Ban
AU - Hyun Jung Jin
AU - Ji-Ho Lee
AU - Young-Hee Nam
AU - Hyo-In Rhyou
AU - Gil-Soon Choi
AU - Gyu Young Hur
AU - Jeong-Hee Choi
AU - Joo-Hee Kim
AU - Chang-Gyu Jung
AU - Seong-Dae Woo
AU - Hwa Young Lee
AU - Mi-Ae Kim
AU - Youngsoo Lee
AU - Sang-Ha Kim
AU - Hyun-Young Lee
AU - Young-Min Ye
PY - 2026
DA - 2026/11/16
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210277
UR - https://www.mdpi.com/1422-0067/27/22/10277
AB - Concerns about worsening allergic disease may contribute to vaccine hesitancy. We evaluated the frequency, severity, and factors associated with self-reported exacerbations after COVID-19 vaccination and described findings after influenza vaccination. In this multicenter observational survey, adults with physician-diagnosed allergic diseases were prospectively enrolled at 14 Korean allergy centers, while vaccination history and post-vaccination outcomes were retrospectively ascertained. Severe exacerbation was defined as requiring emergency department care or hospitalization. Among 1626 COVID-19-vaccinated patients, 281 (17.3%) reported exacerbation; 36 (12.8% of exacerbators; and 2.2% of all vaccinated patients) were severe. Female sex, chronic urticaria, and atopic dermatitis were independently associated with any exacerbation, whereas increasing age and allergic rhinitis were associated with lower odds. Bronchial asthma was independently associated with severe exacerbation (adjusted OR, 3.07; 95% CI, 1.10–8.51). No factor was associated with multiple exacerbations. Biologic therapy and allergen immunotherapy were not associated with increased risk. Exacerbations were reported in 16 of 786 influenza-vaccinated patients (2.0%) and were generally mild. Although self-reported symptom worsening after COVID-19 vaccination was relatively common, severe events were uncommon. COVID-19 vaccination was generally well tolerated, including among patients receiving biologics or allergen immunotherapy.
SN - 1422-0067
ER -